Singulus Technologies (SNG) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
29 Jul, 2026Executive summary
Revenue for Q1 2025 was €16.4 million, down from €20.6 million year-over-year.
EBIT remained slightly positive at €0.5 million, compared to €0.6 million in Q1 2024.
Incoming orders dropped sharply to €6.4 million from €33.2 million year-over-year.
Order backlog as of March 31, 2025, was €67.4 million, slightly lower than €71.6 million a year earlier.
Gross margin improved to 34.6% from 29.4% year-over-year.
Outlook and guidance
Management expects revenue growth and improved earnings for 2025, assuming stabilization in global economic conditions and successful order intake.
All three segments—Solar, Semiconductor, and Life Science—are expected to contribute positively to consolidated earnings.
The company is monitoring geopolitical risks and trade conflicts, which could impact supply chains and order intake.
Segment performance
Semiconductor: Focus on high-precision manufacturing for MRAM, thin-film heads, micro-LEDs, and sensors; strong demand from sensor manufacturers.
Life Science: Expanding wet-chemical and coating technologies for medical, cosmetics, and automotive applications; regulatory compliance and new modules developed.
Solar: Investments in HJT and tandem solar cell technologies; turnkey solutions for industrial production; several new orders for coating technologies.
New business areas: Initial orders received in hydrogen technology (bipolar plates for electrolyzers) and next-generation batteries (solid-state); leveraging existing coating expertise.
Latest events from Singulus Technologies
- 2025 saw revenue fall to €48.3M and EBIT to -€11.7M, but 2026 outlook is positive after refinancing.SNG
Q4 202529 Jul 2026 - Q1-2026 delivered robust revenue and EBIT growth, with 2026 sales set to surge on Solar strength.SNG
Q1 202629 Jul 2026 - 2024 revenue grew, but EBIT stayed negative; outlook hinges on new orders and liquidity.SNG
Q4 202429 Jul 2026 - Order intake doubled and gross margin rose, but sales guidance was cut amid ongoing risks.SNG
Q2 202429 Jul 2026 - Sales, EBIT, and order intake rose, but liquidity and going concern risks remain.SNG
Q3 202429 Jul 2026 - Revenue and orders fell sharply, resulting in losses and heightened liquidity risks.SNG
Q2 202529 Jul 2026 - Sales, EBIT, and order intake fell sharply; refinancing is critical by mid-2026.SNG
Q3 202529 Jul 2026